Which has better earnings & valuation, PODD or IDXX?

IDEXX Laboratories has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.14 $247.10M $4.30 37.69 IDEXX Laboratories $4.30B 10.34 $1.06B $13.58 41.55

Does the media prefer PODD or IDXX?

In the previous week, Insulet had 40 more articles in the media than IDEXX Laboratories. MarketBeat recorded 50 mentions for Insulet and 10 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.99 beat Insulet's score of 0.23 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral IDEXX Laboratories 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PODD or BDX?

In the previous week, Insulet had 39 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 50 mentions for Insulet and 11 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 1.22 beat Insulet's score of 0.23 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Becton, Dickinson and Company 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, PODD or RMD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.14 $247.10M $4.30 37.69 ResMed $5.15B 5.59 $1.40B $10.37 19.13

Is PODD or RMD more profitable?

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% ResMed 27.44% 25.35% 18.69%

Does the media prefer PODD or RMD?

In the previous week, Insulet had 23 more articles in the media than ResMed. MarketBeat recorded 50 mentions for Insulet and 27 mentions for ResMed. ResMed's average media sentiment score of 0.76 beat Insulet's score of 0.23 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral ResMed 12 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.14 $247.10M $4.30 37.69 DexCom $4.66B 6.32 $836.30M $2.34 32.63

Is PODD or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% DexCom 19.31% 33.33% 13.19%

Does the media prefer PODD or DXCM?

In the previous week, Insulet had 31 more articles in the media than DexCom. MarketBeat recorded 50 mentions for Insulet and 19 mentions for DexCom. DexCom's average media sentiment score of 0.93 beat Insulet's score of 0.23 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, STE or PODD?

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.56 $782.30M $7.93 27.34 Insulet $2.71B 4.14 $247.10M $4.30 37.69

Is STE or PODD more profitable?

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% Insulet 10.44% 26.87% 12.01%

Does the media prefer STE or PODD?

In the previous week, Insulet had 45 more articles in the media than STERIS. MarketBeat recorded 50 mentions for Insulet and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Insulet's score of 0.23 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Insulet (PODD) Competitors

$162.06 +0.78 (+0.48%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$162.65 +0.59 (+0.36%)

As of 07/13/2026 07:46 PM Eastern

Compare

PODD vs. IDXX, BDX, RMD, DXCM, and STE

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), ResMed (RMD), DexCom (DXCM), and STERIS (STE). These companies are all part of the "health care equipment" industry.

How does Insulet compare to IDEXX Laboratories?

Insulet (NASDAQ:PODD) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

IDEXX Laboratories has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69
IDEXX Laboratories	$4.30B	10.34	$1.06B	$13.58	41.55

In the previous week, Insulet had 40 more articles in the media than IDEXX Laboratories. MarketBeat recorded 50 mentions for Insulet and 10 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.99 beat Insulet's score of 0.23 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
IDEXX Laboratories	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus price target of $235.25, suggesting a potential upside of 45.16%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 33.11%. Given Insulet's stronger consensus rating and higher possible upside, research analysts plainly believe Insulet is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEXX Laboratories has a net margin of 24.63% compared to Insulet's net margin of 10.44%. IDEXX Laboratories' return on equity of 70.87% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
IDEXX Laboratories	24.63%	70.87%	32.56%

Insulet has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

IDEXX Laboratories beats Insulet on 12 of the 16 factors compared between the two stocks.

How does Insulet compare to Becton, Dickinson and Company?

Insulet (NASDAQ:PODD) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69
Becton, Dickinson and Company	$21.84B	1.94	$1.68B	$3.95	38.96

Insulet currently has a consensus target price of $235.25, suggesting a potential upside of 45.16%. Becton, Dickinson and Company has a consensus target price of $180.29, suggesting a potential upside of 17.16%. Given Insulet's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insulet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Insulet had 39 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 50 mentions for Insulet and 11 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 1.22 beat Insulet's score of 0.23 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Becton, Dickinson and Company	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Insulet has a net margin of 10.44% compared to Becton, Dickinson and Company's net margin of 5.33%. Insulet's return on equity of 26.87% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
Becton, Dickinson and Company	5.33%	15.37%	7.11%

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

55.0% of ResMed shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69
ResMed	$5.15B	5.59	$1.40B	$10.37	19.13

In the previous week, Insulet had 23 more articles in the media than ResMed. MarketBeat recorded 50 mentions for Insulet and 27 mentions for ResMed. ResMed's average media sentiment score of 0.76 beat Insulet's score of 0.23 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
ResMed	12 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, ResMed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Insulet currently has a consensus price target of $235.25, suggesting a potential upside of 45.16%. ResMed has a consensus price target of $260.17, suggesting a potential upside of 31.15%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71
ResMed	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.59

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
ResMed	27.44%	25.35%	18.69%

Summary

ResMed beats Insulet on 10 of the 17 factors compared between the two stocks.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63

Insulet currently has a consensus target price of $235.25, suggesting a potential upside of 45.16%. DexCom has a consensus target price of $84.88, suggesting a potential upside of 11.17%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Insulet had 31 more articles in the media than DexCom. MarketBeat recorded 50 mentions for Insulet and 19 mentions for DexCom. DexCom's average media sentiment score of 0.93 beat Insulet's score of 0.23 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Insulet has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	19.31%	33.33%	13.19%

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to STERIS?

STERIS (NYSE:STE) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Insulet had 45 more articles in the media than STERIS. MarketBeat recorded 50 mentions for Insulet and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Insulet's score of 0.23 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

94.7% of STERIS shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

STERIS currently has a consensus price target of $278.00, suggesting a potential upside of 28.21%. Insulet has a consensus price target of $235.25, suggesting a potential upside of 45.16%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Insulet	10.44%	26.87%	12.01%

STERIS has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Insulet has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69

Summary

STERIS and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.17B	$8.82B	$7.05B	$12.61B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	37.69	16.09	27.15	24.26
Price / Sales	4.14	7.04	587.92	117.88
Price / Cash	25.51	18.40	29.22	49.36
Price / Book	7.52	3.57	10.75	6.29
Net Income	$247.10M	$228.19M	$3.58B	$330.66M
7 Day Performance	0.32%	-2.31%	-2.07%	-1.32%
1 Month Performance	8.26%	-0.62%	3.31%	-0.64%
1 Year Performance	-44.50%	-2.73%	26.35%	19.08%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.6068 of 5 stars	$162.06 +0.5%	$235.25 +45.2%	-44.0%	$11.17B	$2.71B	37.69	5,400	Trending News Analyst Forecast
IDXX IDEXX Laboratories	4.4708 of 5 stars	$564.98 +1.3%	$751.00 +32.9%	+5.8%	$44.00B	$4.30B	41.60	11,000	Analyst Downgrade
BDX Becton, Dickinson and Company	4.5443 of 5 stars	$155.55 -1.6%	$180.29 +15.9%	-12.5%	$43.56B	$21.84B	39.38	72,000	Positive News
RMD ResMed	4.7616 of 5 stars	$218.40 +4.2%	$270.82 +24.0%	-21.9%	$30.41B	$5.15B	21.06	10,600	Analyst Forecast Gap Down High Trading Volume
DXCM DexCom	3.9459 of 5 stars	$72.38 +1.6%	$84.88 +17.3%	-8.4%	$27.49B	$4.66B	30.93	11,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors

PODD vs. IDXX, BDX, RMD, DXCM, and STE

How does Insulet compare to IDEXX Laboratories?

Summary

How does Insulet compare to Becton, Dickinson and Company?

Summary

How does Insulet compare to ResMed?

Summary

How does Insulet compare to DexCom?

Summary

How does Insulet compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insulet (PODD) Competitors

PODD vs. IDXX, BDX, RMD, DXCM, and STE

How does Insulet compare to IDEXX Laboratories?

Which has better earnings & valuation, PODD or IDXX?

Does the media prefer PODD or IDXX?

Do analysts rate PODD or IDXX?

Is PODD or IDXX more profitable?

Which has more risk and volatility, PODD or IDXX?

Do institutionals and insiders hold more shares of PODD or IDXX?

Summary

How does Insulet compare to Becton, Dickinson and Company?

Which has better valuation and earnings, PODD or BDX?

Do analysts prefer PODD or BDX?

Do institutionals & insiders have more ownership in PODD or BDX?

Does the media refer more to PODD or BDX?

Which has more volatility & risk, PODD or BDX?

Is PODD or BDX more profitable?

Summary

How does Insulet compare to ResMed?

Do insiders & institutionals hold more shares of PODD or RMD?

Which has preferable earnings and valuation, PODD or RMD?

Does the media prefer PODD or RMD?

Which has more risk & volatility, PODD or RMD?

Do analysts recommend PODD or RMD?

Is PODD or RMD more profitable?

Summary

How does Insulet compare to DexCom?

Which has preferable valuation & earnings, PODD or DXCM?

Do analysts prefer PODD or DXCM?

Does the media prefer PODD or DXCM?

Do insiders and institutionals have more ownership in PODD or DXCM?

Which has more risk & volatility, PODD or DXCM?

Is PODD or DXCM more profitable?

Summary

How does Insulet compare to STERIS?

Does the media prefer STE or PODD?

Do insiders & institutionals hold more shares of STE or PODD?

Do analysts recommend STE or PODD?

Is STE or PODD more profitable?

Which has more volatility and risk, STE or PODD?

Which has better earnings & valuation, STE or PODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools